Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC
Year: 2022
Type: article
Study design: Clinical Trial
Abstract: Background: CIMAvax-EGF is an epidermal growth factor (EGF)-depleting immunotherapy which has shown survival benefit as a switch maintenance treatment after platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC). The primary objective of this trial is to establish the safety and recommended phase II dose (RP2D) of CIMAvax-EGF in combination with nivolumab as second-line therapy for NSCLC. Methods: Patients with immune checkpoint inhibitor-naive metastatic NSCLC were enrolled using a "3+3" dose-escalation design. Toxicities were graded according to CTCAE V4.03. Thirteen patients (one unevaluable), the majority with PD-L1 0%, were enrolled into two dose levels of CIMAvax-EGF. Findings: The combination was determined to be safe and tolerable. The recommended phase 2 dose of CIMAvax-EGF was 2.4 mg. Humoral response to CIMAvax-EGF was achieved earlier and in a greater number of patients with the combination compared to historical control. Four out of 12 evaluable patients had an objective response.
Source: Frontiers in Oncology
Authors: Rachel Evans, Kelvin Lee, Paul K. Wallace, Mary Reid, Jason Muhitch, Askia Dozier, Circe Mesa, Patricia L. Luaces, Orestes Santos-Morales, Adrienne Groman, Carlos Cedeno, Aileen Cinquino, Daniel T. Fisher, Igor Puzanov, Mateusz Opyrchal, Christos Fountzilas, Tong Dai, Marc Ernstoff, Kristopher Attwood, Alan Hutson, Candace Johnson, Zaima Mazorra, Danay Saavedra, Kalet Leon, Agustin Lage, Tania Crombet, Grace K. Dy
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,950
OpenAlex ID: W4289544404